The Role of Traditional Chinese Medicine in the Regulation of Oxidative Stress in Treating Coronary Heart Disease

Xinyu Yang, Tianmai He, Songjie Han, Xiaoyu Zhang, Yang Sun, Yanwei Xing, and Hongcai Shang

Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
Guang An Men Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China

Correspondence should be addressed to Yanwei Xing; xingyanwei12345@163.com and Hongcai Shang; shanghongcai@126.com

Xinyu Yang and Tianmai He contributed equally to this work.

Received 24 November 2018; Revised 19 January 2019; Accepted 4 February 2019; Published 24 February 2019

Academic Editor: Mithun Sinha

Copyright © 2019 Xinyu Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Oxidative stress has been closely related with coronary artery disease. In coronary heart disease (CHD), an excess of reactive oxygen species (ROS) production generates endothelial cell and smooth muscle functional disorders, leading to a disequilibrium between the antioxidant capacity and prooxidants. ROS also leads to inflammatory signal activation and mitochondria-mediated apoptosis, which can promote and increase the occurrence and development of CHD. There are several kinds of antioxidative and small molecular systems of antioxidants, such as β-carotene, ascorbic acid, α-tocopherol, and reduced glutathione (GSH). Studies have shown that antioxidant treatment was effective and decreased the risk of CHD, but the effect of the treatment varies greatly.

Traditional Chinese medicine (TCM) has been utilized for thousands of years in China and is becoming increasingly popular all over the world, especially for the treatments of cardiovascular diseases. This review will concentrate on the evidence of the action mechanism of TCM in preventing CHD by modulating oxidative stress-related signaling pathways.

1. Introduction

Coronary heart disease (CHD) is one of the primary reasons of death in the world, with 7.4 million deaths in 2013, being responsible for one-third of all deaths [1–3]. By 2020, it is forecasted that CHD will continue to be the prime and most prevalent threat to human life [4]. CHD is multifactorial and concerns intricate interactions between physiological, genetic, and lifestyle factors [5]. In past studies, traditional risk factors of CHD like diabetes, hypertension, smoking, and hyperlipidemia are linked with oxidative stress [6–8]. However, a number of studies have also associated oxidative stress with the mechanism of coronary atherosclerosis and have assessed the markers of oxidative stress, indicating that they can predict the occurrence of CHD [9]. Therefore, oxidative stress is one of the risk factors of CHD, which can affect the prognosis and reduce the survival time and quality of life of patients with CHD [10, 11].

Oxidative stress has been closely related with the mechanism of atherosclerosis and coronary artery disease. Oxidative stress may take place when the antioxidant ability is insufficient to decrease reactive oxygen species (ROS) and other free radicals. When oxidative stress occurs, ROS may generate oxidative modification or lipid peroxidation damage at the deoxyribonucleic acid (DNA) level and protein level with harmful consequences for the structure and function of the vascular system [12, 13]. In CHD, microvascular pathology revealed a higher level of ROS. The production of excess ROS generates endothelial cells and smooth muscle functional disorder, leading to a disequilibrium between the antioxidant capacity and prooxidants, thus leading to inflammatory signal activation and mitochondria-mediated apoptosis, which can promote and increase the occurrence and development of CHD [14, 15].

There are several types of vital antioxidative systems, including superoxide dismutase (SOD), catalase (CAT), and
glutathione peroxidase (GSH-PX). There are also numerous crucial small molecular antioxidants such as β-carotene, ascorbic acid, α-tocopherol, and reduced glutathione (GSH) [16]. Studies have shown that antioxidant treatment was effective and decreased the risk of CHD [17]. Oxidative status records for a particular patient are generally inadequate, and specific antioxidants suitable for that patient are rarely prescribed [18] which influences treatment effectiveness. However, traditional Chinese medicine (TCM) has been utilized for thousands of years in China and is becoming increasingly popular all over the world, especially for the treatment of cardiovascular diseases [19]. Modern pharmacological research has indicated that many Chinese herbal extracts protect the development of cardiovascular diseases through their antioxidating effects [20–22]. A schematic diagram of the mechanisms of ROS is demonstrated in Figure 1. This review will concentrate on the current evidence of the action mechanism of TCM in preventing CHD by modulating oxidative stress-related signaling pathways.

2. Protective Effects of Traditional Chinese Medicine (TCM) and Its Constituent Compounds on Coronary Heart Disease

2.1. Myocardial Infarction (MI). MI is considered as one of the most common forms of ischemic heart disease and is one of the main reasons of death worldwide. A growing body of evidence has indicated that ROS can lead to cell loss following MI and is closely related to the generation of MI [23]. ROS reduction may represent a vital therapeutic target for relieving the damage caused by a MI. Therefore, targeting the production of ROS with all kinds of antioxidants has been shown to decrease oxidative stress-related injury and therefore improve MI status.

2.1.1. The Bioactive Ingredients of Traditional Chinese Medicine. Salvia miltiorrhiza: Salvia miltiorrhiza, a famous Chinese herb medicine, has been widely used in treating cardiovascular diseases [24]. Studies showed that it could relieve small artery circulation, decrease ROS production [25–27], restrain cell apoptosis [27–29], and protect the heart against ischemia-reperfusion injury [30–32]. *Salvianolic acid* (SAL, C$_{36}$H$_{30}$O$_{16}$; C$_{26}$H$_{22}$O$_{10}$) and *tanshinone* (TAN, C$_{18}$H$_{12}$O$_{3}$; C$_{19}$H$_{18}$O$_{3}$), hydrophilic and lipophilic compounds, are extracted from *Salvia miltiorrhiza* [33]. Wang et al. [34] studied the use of the MI models to evaluate the cardioprotective functions of SAL and TAN in rats. Both echocardiographic and infarct sizes were assessed after surgery, while gene activity was detected by microarray analysis and validated by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). These results depicted that SAL is possibly mediated by the downregulation of factors participating in oxidative stress and apoptosis, while TAN is
probably mediated by the suppression of intracellular calcium and cell adhesion pathways in the MI.

Danshensu (DSS, \( C_{32}H_{38}O_6 \)), the main water-soluble ingredient of \textit{Salvia miltiorrhiza}, has also been studied as a significant compound. In a study [35], DSS was detected in an ischemia-reperfusion (I/R) model to research its cardioprotective function. The results showed that DSS significantly reduced the level of creatine kinase and lactate dehydrogenase and that DSS had ROS scavenging activity and enhanced endogenous antioxidants such as SOD, CAT, and catalase (MDA), GSH-PX, and heme oxygenase-1 (HO-1) activities through stimulation of the nuclear factor erythroid-2-related factor 2 (Nrf2) signaling pathway which was regulated by serine/threonine kinase (Akt) and extracellular signaling-regulated kinase 1/2 (ERK1/2) signaling pathway in a western blot analysis. The mechanism might be associated with the improvement of the antioxidant defense system by stimulating Akt/ERK1/2/Nrf2 signaling pathways [36, 37].

**Astragalin:** Astragalin (\( C_{21}H_{20}O_11 \)) is a flavonoid that is extracted from the leaves of \textit{Rosa agrestis}, persimmon, or green tea seeds. A large number of studies have indicated that astragalin has wide pharmacological activities, covering anti-inflammatory, antioxidative, and other beneficial activities [38–40]. A study [41] that assessed the cardioprotective functions of astragalin against I/R injury in the rat heart by Langendorff apparatus has been conducted. The results revealed that astragalin pretreatment ameliorated myocardial function. SOD activity and the glutathione/glutathione disulfide (GSH/GSSG) ratio were dramatically enhanced, and the levels of MDA, tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)), intracellular ROS, and interleukin-6 (IL-6) were reduced in the astragalin-treated groups. Thus, astragalin displayed cardioprotective functions through its antiapoptotic, antioxidative, and anti-inflammatory activities [41–43].

**Ophiopogonin D (OP-D):** OP-D (\( C_{19}H_{20}O_9 \)) is a significantly valid monomeric ingredient used in the Shenmai injection (SM-I). It is reported that it has a wide range of biological activities, including antiapoptotic effects, antioxidative, and anti-inflammatory actions [44–47]. The rat model of myocardial ischemia-reperfusion (MI/R) damage was produced by ligation of the left anterior descending coronary artery to study the protective actions and underlying mechanisms of OP-D and SM-I [48]. The study found that OP-D and SM-I act by inducing cardioprotection on MI/R injury by regulating cardiac function, reducing acute dehydrogenase and creatine kinase (CK) generation, decreasing infarct size, and improving the injured cardiac structures. Cardioprotection by OP-D and SM-I was mediated by activating the phosphoinositide 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) signaling pathway and suppressing the nuclear factor-\( \kappa \)B (NF-\( \kappa \)B) signaling pathway [49, 50].

**Curcumin:** Curcumin (\( C_{21}H_{20}O_6 \)), used both as a seasoning and a traditional medicine, is a natural compound derived from the roots of \textit{Curcuma longa} \textit{L.} It has various pharmacological activities such as anti-inflammatory, antioxidant, and anticarcinogenic activities in different models [51–53]. In a study [54], the possible protective function of \textit{curcumin} on cardiac function in MI/R rats was researched. The rats suffered from myocardial injuries through ligation of the left anterior descending coronary artery. Afterwards, lipid peroxidation products and antioxidant enzymes were evaluated in the myocardial tissue. The result showed that \textit{curcumin} might decrease the ventricle of coronary heart disease via activating the JAK2/STAT3 signal pathway, reducing oxidative damage and suppressing myocardial apoptosis [55–57].

**Punicalin (PUN):** PUN (\( C_{20}H_{20}O_{10} \)), a main bioactive constituent in pomegranate juice, has been tested for neuroprotective functions against cerebral ischemia-reperfusion (I/R) injury by antioxidative mechanisms [58, 59]. Another study [60] investigated if PUN offers cardioprotective effects against MI/R damage and the potential mechanisms. MI/R was achieved by ligating the left anterior descending coronary artery. PUN acts by ameliorating cardiac function and infarct size, decreasing serum creatine kinase-MB (CK-MB) and lactate dehydrogenase, and inhibiting myocardial apoptosis against MI/R damage. These results showed that PUN protects against I/R-induced ROS and myocardial damage by activating adenosine monophosphate-activated protein kinase (AMPK) [60, 61].

**Barbaloin (BAR):** BAR (\( C_{21}H_{22}O_9 \)) is the major medicinal ingredient of \textit{Aloe vera} belonging to the liliaceous plant group that has good antioxidant properties [62]. Zhang et al. [63] investigated if BAR offers cardioprotection in the MI myocardial damage. BAR was intragastrically administered to rats before MI operation. The result showed that BAR pretreatment efficiently suppressed I/R-induced ROS and inflammatory effects by activating AMPK signaling in MI/R rat hearts [62–65].

**Oxysophoridine (OSR):** OSR (\( C_{15}H_{24}N_2O_2 \)), a natural alkaloid from the Chinese herbal medicine \textit{Sophora alopecuroides} \textit{L.}, can play multiple pharmacological roles such as the suppression of oxidative stress and apoptosis [66, 67]. A study [68] assessed the cardioprotective effect of OSR against MI in rats. OSR decreased infarction size and the levels of myocardial enzymes, including the CK-MB, cardiac troponin T, and lactate dehydrogenase. A decreased level of MDA was noticed while increased levels of catalase, SOD, and glutathione peroxidase activity, and nonenzymatic scavenger glutathione were also verified in OSR-treated rats. In addition, OSR suppressed the activities of various inflammatory cytokines [69, 70]. The results showed that OSR relieves myocardial damage in the rat model of acute myocardial infarction (AMI) and that the cardioprotective effects may be associated with antiapoptotic, anti-inflammatory, and antioxidative mechanisms.

**Gentianella acuta (\textit{G. acuta})**: \textit{G. acuta} (\( C_{21}H_{20}O_8 \)) is extensively used for the therapy of coronary heart disease in Mongolian medicine. It is commonly known as “Wenxincao” in traditional Chinese medicine [71]. The potential protective effect of \textit{G. acuta} on myocardial I/R injury by using the Langendorff apparatus in isolated rats was studied [72]. Some hemodynamic parameters were logged during the perfusion. These results showed that the xanthones from \textit{G. acuta} dramatically ameliorated myocardial function and enhanced...
the levels of SOD, succinate dehydrogenase (SDH), CAT, malate dehydrogenase (MDH), adenosine triphosphate (ATP), and the proportion of GSH/GSSG while inhibiting the levels of CK, MDA, and LDH. Moreover, xanthones could upregulate the Bcl-2 protein and downregulate the Bax protein. In short, xanthones from G. acuta displayed a cardioprotective effect on myocardial I/R damage via antioxidative and antiapoptosis activities [73–76].

Azafrin: Centranthera grandiflora Benth. is an ethnic drug known as Ye-Can-Dou-Gen (YCDG) and has been extensively used to cure cardiovascular system diseases in China. Azafrin (C_{27}H_{30}O_{4}), a carotene antioxidant, is one of the richest active compounds in YCDG [77]. Yang et al. [78] investigated the cardioprotective capacity of azafrin on the MI and MI/R damage to understand its potential myocardium preservation mechanisms. By experimental procedures, the results indicated that azafrin treatment significantly ameliorated heart function and infarct size in rats; reduced the levels of myocardial enzymes, cardiac troponin I (cTnI), and MDA; and increased SOD activity in vivo. In a word, azafrin displayed cardioprotective effects against myocardial damage through activation of the Nrf2-antioxidant response element (ARE) pathway [79].

2.1.2. Traditional Chinese Medicine Decoction. Bao-Xin-Tang (BXT): BXT is a Chinese herbal compound used to treat coronary heart disease and is made of Codonopsis pilosula, Atractylodes macrocephala, Astragalus, Fructus crataegi, etc. Previous studies have verified that it can ameliorate blood circulation to protect the myocardium of patients with MI [80]. A study [81] designed to explore if BXT offers cardioprotection against MI has been conducted. The rat model of MI was made by the ligation of the left anterior descending coronary artery. The data suggested that BXT could decrease the infarction size, myeloperoxidase, interleukin-6 (IL-6), and levels of C-reactive protein (CRP) and enhance SOD activities and anti-inflammatory media such as interleukin-10 (IL-10). Thus, the functions of BXT may be associated with antioxidant and anti-inflammation properties [82, 83].

Dan-Shen-Yin (DSY): DSY, including sandalwood Fructus amomi and Salvia miltiorrhiza, is a famous Chinese herbal formula which is extensively used for the therapy of CHD [84, 85]. A study [86] explored whether DSY could protect from MI. The left anterior descending branch of the coronary artery was ligated to induce myocardial ischemia in rats, measuring the infarction size, inflammation factor, and antioxidative enzyme activities. DSY decreased the infarction size, IL-6, CRP, TNF-α, and MAD, as well as enhanced SOD activities and glutathione [87, 88]. These results suggested that DSY plays a remarkable role against ischemic myocardial damage in rats, probably through an anti-inflammatory reaction and antioxidative properties.

2.1.3. Patented Drugs from Traditional Chinese Medicine. Dunye Guanxintai (DG): DG, a traditional Chinese herbal medicine formula, is extracted from the rhizomes of Dioscorea zingiberensis and is widely used for the treatment of angina, hyperlipidemia, and coronary heart disease [89, 90]. A study [91] explored that DG ameliorates myocardial I/R damage by suppressing caspase-1 activity and neutrophil infiltration. The result suggested that DG restrained neutrophil infiltration and decreased the interleukin-1 beta (IL-1β). In addition, DG suppressed caspase-1 activity and activatory AMPK phosphorylation in rat hearts. Thus, DG may be able to suppress the inflammatory response by the AMPK pathway [90, 91].

Hongjingtian injection (HJT): HJT is extracted from Rhodiola rosea and could prevent all kinds of vascular diseases like coronary heart disease and angina [92]. A study [93] assessed the cardioprotective effects of HJT. The experiments showed that HJT suppressed H/R-induced apoptosis and adjusted the expression of apoptosis-related proteins caspase 3 and Bcl-2. In addition, HJT obviously regulated the activity of the Akt, ERK/mTOR, and Akt/Beclin-1 pathways in cardiac cell autophagy. HJT prominently reduced the infarct size and ameliorated cardiac function and enhanced the light chain 3B (LC-3B) protein expression in the coronary ligation rat model. As a result, HJT reduced myocardial injury by adjusting the balance of apoptosis and autophagy and by decreasing ROS levels [94, 95].

Guanxintai (GXT): GXT, a Chinese compound formula, is often used in the treatment of cardiovascular diseases and is mainly composed of Ginseng, Astragalus, Rehmannia, Ophiopogon root, etc. Previous studies have verified the cardioprotective effects of GXT on the angina [96–99] and arrhythmia [100], as well as its inhibitory actions on blood lipid levels [101]. Yang et al. [102] studied the protective actions of GXT on ischemic cardiomyocytes and the related antioxidative effects. The research findings showed that GXT decreased the degree of myocardial cell injury and apoptosis and partly ameliorated cardiac function after MI. Furthermore, GXT restrained the ROS level and reduced NADPH oxidase (NOX) and mitogen-activated protein kinase (MAPK) protein expression. Therefore, the cardioprotective effects of GXT are exerted by the activity of the antioxidative NOX suppression [103, 104].

Cardiotonic pill (CP): CP includes Salvia miltiorrhiza, Borneol, and Panax notoginseng and is extensively used for the treatment of ischemic angina pectoris. A study [105] explored the underlying mechanisms of CP antioxidative activity. Male rats had left anterior descending artery ligation, and then, reperfusion was performed. The result suggested that CP decreased myocardial damage, ROS, and microcirculation disturbance. CP prominently suppressed I/R-induced NOX subunit p67phox, gp91phox, and p47phox protein expression. These data indicated that the CP alleviated I/R-induced rat myocardial damage and the disorder of microcirculation by inhibiting NOX activity [105–107].

Shenxian-shengmai (SXSM): SXSM oral liquid, a Chinese compound formula, has been widely used for bradycardias in clinical practice [108, 109]. MI, especially in right coronary-associated cardiac diseases, can give rise to bradycardias. A study [110] evaluated the functions of SXSM on bradycardias and cardiac insufficiency caused by myocardial I/R damage. Results showed that SXSM enhanced heart rate and protected from myocardial I/R damage. The study also discovered that SXSM ameliorated
myocardial interstitial dilatation and the structural changes of myocardial cells. At the same time, SXSM protected myocardial cells against ROS induced by H2O2 and I/R damage by decreasing the intracellular levels of ROS. Furthermore, SXSM enhanced the activity of SOD and aggrandized the content of GSH by accelerating the glutamate-cysteine ligase catalytic subunit (GCLC) expression and GSH-Px activity, suggesting the antiarrhythmia and cardioprotective effects [111] (Table 1).

| Type of TCM | TCM (molecular formula) | Type of study | Mechanism of action | References |
|-------------|-------------------------|---------------|---------------------|------------|
| The bioactive ingredients of TCM | SAL (C36H30O16, C26H12O16), TAN (C29H12O5, C19H10O2) | In vivo | Downregulation of factors participated in oxidative stress and apoptosis; inhibition of intracellular calcium and cell adhesion pathways | Wang et al. [129] |
| | Danshensu (C8H16O3) | In vivo | Activation of the Akt/ERK1/2/Nrf2 signaling pathway | Yu et al. [35] |
| | Astragalin (C21H20O11) | In vivo | Antiapoptotic, antioxidative, and anti-inflammatory activities | Qu et al. [41] |
| | OP-D (C46H70O16) | In vivo | Activating JAK2/STAT3 signal pathway, reducing oxidative damage and suppressing myocardium apoptosis | Liu et al. [111] |
| | Curcumin (C21H20O12) | In vivo | Activation of AMPK | Ding et al. [60] |
| | Punicalagin (C48H70O16) | In vivo | Antioxidative, anti-inflammatory activity | Zhang et al. [93] |
| | Barbaloin (C21H22O9) | In vivo | Antiapoptotic, antioxidative, and anti-inflammatory activities | Meng et al. [68] |
| | G. acuta (C13H8O2) | In vivo | Activities of antioxidative and antiapoptosis | Wang et al. [81] |
| | Azafrin (C27H38O4) | In vivo, in vitro | Activation of the Nrf2-ARE pathway | Yang et al. [158] |
| Traditional Chinese medicine decoction | Bao-Xin-Tang | In vivo | Antioxidant and anti-inflammation properties | Wang et al. [81] |
| | Dan-Shen-Yin | In vivo | Anti-inflammatory and antioxidant properties | Yan et al. [86] |
| Patented drugs from traditional Chinese medicine | Dunye Guanxinning | In vivo | Inhibits inflamasome activity through the AMPK pathway | Zhang et al. [91] |
| | Hongjingtian injection Guanxintai Cardiotonic pill Shenxian-shengmai | In vivo, in vitro | Decreasing myocardial oxidative damage Reduced NOX and MAPK proteins Inhibiting NOX activity | Zhang et al. [93] Yang et al. [158] Yang et al. [105] |
| | | In vivo | Enhanced the activity of SOD and aggrandized the content of GSH | Zhao et al. [110] |

2.2. Ischemic Heart Failure

2.2.1. Patented Drugs from Traditional Chinese Medicine. Qi-shen-yi-qi (QSYQ): QSYQ, a formula used for the routine treatment of HF in China, includes Radix, Astragali mongoli, Salvia miltiorrhiza Bunge, Flos Lonicerae, Scrophularia, Radix Aconiti Lateralis preparata, and Radix glycyrrhiza and has been proven to ameliorate cardiac function by downregulating the Renin-Angiotensin-Aldosterone System (RAAS) activity [112, 113]. A study [114] surveyed the treatment with QSYQ ischemic heart failure prevention by alleviating oxidative stress and suppressing inflammation. Rats were processed by coronary artery ligation, and then, the indicators of fibrosis such as Masson dyeing, matrix metalloproteinases (MMPs) and collagens, and inflammation factors were detected. The study demonstrated that QSYQ ameliorated cardiac function via reducing the degree of myocardial fibrosis, TNF-α, NF-κB, and IL-6-STAT3 pathways and modulating angiotensin II-NADPH oxidase-RAS-MMP pathways [114, 115].

Tongxinluo (TXL): TXL is a prescription compound of Chinese medicine and has been verified as having anti-inflammatory, lipid-lowering, and antioxidant effects in ameliorating ischemic heart diseases [116]. A study [117] explored if TXL protected against the pressure overload-induced ischemic heart failure in mice. The transverse aortic constriction (TAC) operation was carried in mice to induce ischemic heart failure. TXL ameliorated cardiac function and relieved cardiac hypertrophy and myocardial fibrosis after treatment. Furthermore, TXL also enhanced
myocardial capillary density and reduced oxidative stress damage by activating the vascular endothelial growth factor (VEGF)/Akt/eNOS signaling pathway [118].

YiQiFuMai powder injection (YQFM): YQFM, a Chinese medicinal formula rediscovered on the basis of Shengmai San, is extracted from Panax ginseng, Ophiopogon japonicus, and Schisandra chinensis and is widely used to treat angina and ischemic heart failure [119, 120]. Another study [121] noticed the therapeutic effect of YQFM on coronary artery occlusion-induced ischemic heart failure. Ischemic heart failure was induced by coronary artery occlusion in mice. After treatment with YQFM, the result displayed that YQFM can reduce LDH and CK activities and levels of MDA, and hydroxyproline (HYP). Moreover, YQFM relieves coronary artery occlusion-induced ischemic heart failure by ameliorating the cardiac function and structure damage, oxidative stress, and cell apoptosis and suppressing the MAPK pathways [122–125].

2.4. Coronary Atherosclerotic Heart Disease

2.4.1. Single Chinese Herbal Medicines. Radix notoginseng: Radix notoginseng, a traditional Chinese medicine extracted from the roots of Panax notoginseng, is widely planted and used as an herbal medicine in Southern China. It indicates multiple biological activities, and it is also used as a therapeutic agent for coronary heart disease and peroxidation [130, 131]. A study [132] explored the cardioprotection effect of Radix notoginseng in cardiovascular system diseases related to hyperlipidemia and excess cholesterol. The rat model was established by using a dietary supplement to keep a high fat diet. Radix notoginseng led to a significant reduction in cholesterol and triglycerides, with a rise in the high-density lipoprotein–cholesterol. In addition, Radix notoginseng ameliorated antioxidant status through the SOD and glutathione peroxidase (GPx) activity and decreased the lipid peroxidation [133, 134]. The result showed that Radix notoginseng could ameliorate lipid distributions, suppress peroxidation, and enhance antioxidant enzymes activity, thereby decreasing the occurrence of CHD.

Pomegranate: pomegranate fruit is abundant in polyphenols, has an antioxidant activity, and has been suggested to have advantageous effects in cardiovascular disease [135]. The impacts of pomegranate on ROS and inflammation in the model of coronary heart disease in mice have been studied [136, 137]. Transgenic mice were treated with pomegranate extract [138]. Pomegranate could improve cardiac enlargement and electrocardiogram (ECG) abnormalities by reducing macrophage infiltration, lipid accumulation, ROS, and monocyte chemotactic protein-1 in transgenic mice with

---

### Table 2: The role of traditional Chinese medicine (TCM) in the regulation of reactive oxygen species (ROS) in ischemic heart failure and angina.

| Type of disease | Type of TCM (molecular formula) | Type of study | Mechanism of action | References |
|-----------------|---------------------------------|---------------|---------------------|------------|
| Ischemic heart failure | Patented drugs from traditional Chinese medicine Qi-shen-yi-qi | In vivo | Recovering angiotensin II-NADPH oxidase-ROS-MMP pathways | Li et al. [114] |
| Stable angina | Tongxinluo YiQiFuMai powder injection | In vivo | Activation of the VEGF/Akt/eNOS signaling pathway | Wang et al. [117] |
| Stable angina | Tongmai Yangxin pill | In clinic | Ameliorating cardiac function and structure damage, oxidative stress, and cell apoptosis and inhibiting the MAPK signaling pathways | Pang et al. [121] |

ROS: reactive oxygen species; MMPs: matrix metalloproteinases; VEGF: vascular endothelial growth factor; Akt: serine/threonine kinase; eNOS: endothelial nitric oxide synthase; MAPK: mitogen-activated protein kinase.
coronary atherosclerotic plaque. These results indicated that the protective effect of pomegranate against atherosclerosis may relate to reduce inflammation and ROS.

2.4.2. Patented Drugs from Traditional Chinese Medicine. Shengmai San (SMS): SMS includes Panax ginseng, Schisandra chinensis, and Ophiopogon and is a Chinese patent medicine used to treat CHD with antioxidative ability [139]. There was a study [140] which explored the influence of SMS on lipid peroxides and antioxidant reactions in the heart of cholesterol-raised rats. Antioxidant activities and ROS markers in the heart of rats were assessed. Results suggested that GSH-Px, glutathione-S-transferase (GST), and SOD activities were slightly improved after the SMS treatment [141] (Table 3).

3. Discussion

Awareness of the importance of ROS in CHD pathogenesis and the development of novel treatments has increased [142]. As a crucial resource of treatment, TCM has multiple bioactivities with antioxidative ability [143, 144]. As a result, we summarized the research progress of TCM on the treatment of CHD by regulating ROS.

During MI, mechanisms of pathogenesis are associated with a number of factors, like the large amount of free radical generation, enhanced inflammation, and apoptosis [145]. When MI/R injury happens, cardiac intracellular calcium overload can increase XO synthesis and NOX, resulting in a rapid increase of ROS generation [146]. OSR cardioprotection, CP, and SXSM against MI in rats were correlated with antioxidant properties, particularly regarding NOX. Meanwhile, inflammatory signaling pathways are related to the occurrence and development of CHD, and I/R injury is closely connected with increased inflammation [147]. Astragalin, Barbaloin, BXT, and DSY can act on various targets such as suppression of NOX and the rise of GSH, which efficiently decreases ROS injury after I/R damage. Moreover, the anti-inflammatory action of TCM is, at least partly, attributed to its antioxidant effects. A number of studies have also indicated that the upregulation of several antiapoptotic factors and proapoptotic genes, such as the Bcl-2 and Bax, plays a vital function in the ischemic tissue [148, 149]. Curcumin, G. acuta, HJT, and GXT offer cardioprotection by ameliorating heart functions, inhibiting the ROS of cardiac cells, enhancing the release of antioxidant enzymes, and restraining mitochondria disorder and cardiomyocyte apoptosis during I/R damage. There is growing evidence that the PI3K/Akt and Nrf2 pathways help in ROS resistance and play a key function in improving myocardial cell survival [150, 151]. Activating antiapoptotic signaling pathways such as Nrf2 and PI3K/Akt could adjust Bcl-2 and suppress caspase c activation. Therefore, a large number of studies have shown that TCM treatment, such as SAL, TAN, DDS, OP-D, and azafarin, could decrease cardiomyocyte ROS and apoptosis through activation of the Nrf2 and PI3K/Akt signaling pathways during I/R damage. AMPK can also upregulate the cell antioxidant enzymes such as SOD and catalase, thereby decreasing oxidative damage [152]. The activation of the AMPK signaling pathway during I/R injury has been thought to be a mechanism of treatment against ROS and myocardial damage [153]. Above all, PUN, Barbaloin, DG, and GXT have been noticed to improve mitochondrial damage and ROS by the AMPK signaling pathway.

In ischemic heart failure, the oxidative stress system is activated, thereby significantly promoting coronary arterial disease and damaging cardiac myocytes [154]. In this pathway, NOX plays an important role in the occurrence and progression of IHF [155, 156]. At the same time, increased oxidative stress combined with the activation of a variety of inflammatory and apoptosis pathways significantly influence the effect on the occurrence and development of ischemic heart failure [157]. TCM has been used to cure ischemic heart failure for thousands of years. A lot of TCMs, such as QSYQ, TXL, and YQFM, showed cardioprotection against HF by alleviation of apoptosis, inflammation, and ROS.

Increased oxidative stress, disturbed lipid metabolism, and increased inflammation are critical factors in the occurrence and development of atherosclerosis and subsequent CHD [158, 159]. Radix notoginseng, pomegranate, and SMS offer tissue damage protection, attributed to ROS, by decreasing lipid peroxidation and enhancing the activity of antioxidant enzymes. In angina, pathogenesis mainly involves energy metabolism, ROS, and inflammation [160]. TMYX may have therapeutic actions by ameliorating myocardial energy supply dysfunction and amino acid disorders and by reducing ROS and inflammation.

4. Conclusions

In conclusion, there is overwhelming evidence that oxidative stress is associated with the pathogenesis of CHD. TCM therapy has unique advantages in CHD. In recent years, Chinese medicine has made great progress in the treatment of CHD,
which can effectively ameliorate the symptoms of patients and improve the quality of life of patients. Compared with Western medicine, it has significant therapeutic effects, few side effects, and no obvious drug dependence. The treatment of this disease by TCM has a broad prospect, and it is worthy of further promotion and development.

Conflicts of Interest
All authors claim that there is no conflict of interests about the publication of this review.

Authors’ Contributions
Xinyu Yang, Yanwei Xing, and Hongcai Shang designed the idea for drafting this review. Xinyu Yang and Tianmai He collected the documents and wrote the paper. Songjie Han contributed to Discussion. Xiaoyu Zhang and Yang Sun revised and edited the review. All authors commented on the manuscript.

Acknowledgments
The work was supported by the National Key Research and Development Program of China (Grant No. 2017YFC1700400), the National Natural Science Foundation of China (Grant Nos. 81725024 and 81430098) and National High-Level Talent Special Support Plan (No. W02020052), the clinical base project of the State Administration of Traditional Chinese Medicine of China (JDZX2015007), and the outstanding project of the Beijing University of Chinese Medicine (2015-JYBXJQ001).

References
[1] L. Anderson, N. Oldridge, D. R. Thompson et al., “Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis,” Journal of the American College of Cardiology, vol. 67, no. 1, pp. 1–12, 2016.
[2] X. Yang, Y. Li, X. Ren et al., “Effects of exercise-based cardiac rehabilitation in patients after percutaneous coronary intervention: a meta-analysis of randomized controlled trials,” Scientific Reports, vol. 7, no. 1, article 44789, 2017.
[3] B. B. Kelly, J. Narula, and V. Fuster, “Recognizing global burden of cardiovascular disease and related chronic diseases,” Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, vol. 79, no. 6, pp. 632–640, 2012.
[4] K. Kaur, G. Bedi, M. Kaur, A. Vij, and I. Kaur, “Lipid peroxidation and the levels of antioxidant enzymes in coronary artery disease,” Indian Journal of Clinical Biochemistry, vol. 23, no. 1, pp. 33–37, 2008.
[5] N. Ahmad and R. Bhopal, “Is coronary heart disease rising in India? A systematic review based on ECG defined coronary heart disease,” Heart, vol. 91, no. 6, pp. 719–725, 2005.
[6] F. Cosentino, J. C. Sill, and Z. S. Katusic, “Role of superoxide anions in the mediation of endothelium-dependent contractions,” Hypertension, vol. 23, no. 2, pp. 229–235, 1994.
[7] D. G. Harrison, “Cellular and molecular mechanisms of endothelial cell dysfunction,” The Journal of Clinical Investigation, vol. 100, no. 9, pp. 2153–2157, 1997.
[8] S. Kerr, M. J. Brosnan, M. McIntyre, J. L. Reid, A. F. Dominiczak, and C. A. Hamilton, “Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium,” Hypertension, vol. 33, no. 6, pp. 1353–1358, 1999.
[9] S. Tsimikas, “In vivo markers of oxidative stress and therapeutic interventions,” The American Journal of Cardiology, vol. 101, no. 10A, pp. 34D–42D, 2008.
[10] R. P. Juni, H. J. Duckers, P. M. Vanhoutte, R. Verhulst, and A. L. Moens, “Oxidative stress and pathological changes after coronary artery interventions,” Journal of the American College of Cardiology, vol. 61, no. 14, pp. 1471–1481, 2013.
[11] B. Q. Li, D. M. Liu, and W. Cui, “Advances in the study of sudden cardiac death after revascularization in patients with coronary heart disease,” Chinese Circulation Journal, vol. 33, no. 11, pp. 1134–1137, 2018.
[12] J. A. Leopold and J. Loscalzo, “Oxidative risk for atherothrombotic cardiovascular disease,” Free Radical Biology and Medicine, vol. 47, no. 12, pp. 1673–1706, 2009.
[13] E. Lubos, J. Loscalzo, and D. E. Handa, “Thioloxidase peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities,” Antioxidants & Redox Signaling, vol. 15, no. 7, pp. 1957–1997, 2011.
[14] F. Tullio, C. Angotti, M.-G. Perrelli, C. Penna, and P. Pagliaro, “Redox balance and cardioprotection,” Basic Research in Cardiology, vol. 108, no. 6, p. 392, 2013.
[15] C. Zhang, H. Yu, Y. Shen, X. Ni, S. Shen, and U. N. Das, “Polyunsaturated fatty acids trigger apoptosis of colon cancer cells through a mitochondrial pathway,” Archives of Medical Science, vol. 11, no. 5, pp. 1081–1094, 2015.
[16] J. A. Leopold, “Antioxidants and coronary artery disease: from pathophysiology to preventive therapy,” Coronary Artery Disease, vol. 26, no. 2, pp. 176–183, 2015.
[17] B. J. Willcox, J. D. Curb, and B. L. Rodriguez, “Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies,” The American Journal of Cardiology, vol. 101, no. 10, pp. S75–S86, 2008.
[18] M. J. Kendall and S. L. Nuttall, “Anti-oxidant therapy for the treatment of coronary artery disease,” Expert Opinion on Investigational Drugs, vol. 8, no. 11, pp. 1763–1784, 1999.
[19] D. Wang, E. J. Calabrese, B. Lian, Z. Lin, and V. Calabrese, “Hormesis as a mechanistic approach to understanding herbal treatments in traditional Chinese medicine,” Pharmacology & Therapeutics, vol. 184, pp. 42–50, 2018.
[20] M. Rajadurai and P. Stanely Mainzen Prince, “Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences,” Toxicology, vol. 228, no. 2–3, pp. 259–268, 2006.
[21] L. Wu, H. Qiao, Y. Li, and L. Li, “Protective roles of puerarin and Danshensu on acute ischemic myocardial injury in rats,” Phytomedicine, vol. 14, no. 10, pp. 652–658, 2007.
[22] C.-s. Li, Z.-q. Qu, S.-s. Wang et al., “Effects of Suxiaoxiao Jiuixin pill (速效救心丸) on oxidative stress and inflammatory response in rats with experimental atherosclerosis,” Journal of Traditional Chinese Medicine, vol. 31, no. 2, pp. 107–111, 2011.
[23] F. Bagheri, V. Khorri, A. M. Alizadeh, S. Khalighfard, S. Khodayari, and H. Khodayari, “Reactive oxygen species-mediated cardiac-reperfusion injury: mechanisms and therapies,” Life Sciences, vol. 165, pp. 43–55, 2016.
[24] S. Y. Jiang, J. C. Tong, R. Y. Sun, and H. T. Xie, “Meta-analysis of compound Danshen dropping pills (DSP) in treating coronary heart disease angina," *Practical Pharmacy and Clinical Remedies*, vol. 10, no. 6, pp. 334–337, 2007.

[25] X. Zhou, S. W. Chan, H. L. Tseng et al., “Danshensu is the major marker for the antioxidant and vasorelaxation effects of Danshen (Salvia miltiorrhiza) water-extracts produced by different heat water-extractions," *Phytotherapy*, vol. 19, no. 14, pp. 1263–1269, 2012.

[26] G. R. Zhao, H. M. Zhang, T. X. Ye et al., “Characterization of the radical scavenging and antioxidant activities of Danshensu and salvianolic acid B," *Food and Chemical Toxicology*, vol. 46, no. 1, pp. 73–81, 2008.

[27] Q. T. Zhao, Q. M. Guo, P. Wang, and Q. Wang, “Salvianic acid A inhibits lipopolysaccharide-induced apoptosis through regulating glutathione peroxidase activity and malondialdehyde level in vascular endothelial cells," *Chinese Journal of Natural Medicines*, vol. 10, no. 1, pp. 53–57, 2012.

[28] G.-D. Yang, H. Zhang, R. Lin et al., “Down-regulation of CD40 gene expression and inhibition of apoptosis with Danshensu in endothelial cells," *Basic & Clinical Pharmacology & Toxicology*, vol. 104, no. 2, pp. 87–92, 2009.

[29] Y. Guan, Y. Yin, Y.-R. Zhu et al., “Dissection of mechanisms of a Chinese medicinal formula: Danhong injection therapy for myocardial ischemia/reperfusion injury in vivo and in vitro," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 972370, 12 pages, 2013.

[30] B. L. Zhao, W. Jiang, Y. Zhao, J. W. Hou, and W. J. Xin, “Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury," *Biochemistry and Molecular Biology International*, vol. 38, no. 6, pp. 1171–1182, 1996.

[31] X.-Y. Le, C.-L. Chen, L. Ma, N. Zhao, Y.-Q. Tang, and X.-Q. Liu, “Effects of Danshensu on the incidence of ischemia-reperfusion induced arrhythmia in hypertrophy rat heart," *Chinese Journal of Natural Medicines*, vol. 6, no. 6, pp. 461–465, 2008.

[32] Y. Yin, Y. Guan, J. Duan et al., “Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation," *European Journal of Pharmacology*, vol. 699, no. 1-3, pp. 219–226, 2013.

[33] M. Li, C. Zhao, R. N. Wong, S. Goto, Z. Wang, and F. Liao, "Inhibition of shear-induced platelet aggregation in rat by tetramethylypyrazine and salvianolic acid B," *Clinical Hemorheology and Microcirculation*, vol. 31, no. 2, pp. 97–103, 2004.

[34] X. Wang, Y. Wang, M. Jianger et al., “Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways," *Journal of Ethnopharmacology*, vol. 135, no. 3, pp. 662–671, 2011.

[35] J. Yu, L. Wang, M. Akinji et al., “Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling," *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 9, pp. 14793–14804, 2015.

[36] Y. Tang, M. Wang, X. le et al., “Antioxidant and cardioprotective effects of Danshensu (3-3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats," *Phytotherapy*, vol. 18, no. 12, pp. 1024–1030, 2011.

[37] J. Liu, H. M. Shen, and C. N. Ong, “Role of intracellular thiol depletion, mitochondrial dysfunction and reactive oxygen species in Salvia miltiorrhiza-induced apoptosis in human hepatoma HepG2 cells," *Life Sciences*, vol. 69, no. 16, pp. 1833–1850, 2001.

[38] M.-S. Kim and S.-H. Kim, “Inhibitory effect of astragalin on expression of lipopolysaccharide-induced inflammatory mediators through NF-kB in macrophages," *Archives of Pharmacal Research*, vol. 34, no. 12, pp. 2101–2107, 2011.

[39] O. Burmistrova, J. Quintana, J. G. Díaz, and F. Estévez, “Astragalin heptacetate-induced cell death in human leukemia cells is dependent on caspases and activates the MAPK pathway," *Cancer Letters*, vol. 309, no. 1, pp. 71–77, 2011.

[40] I. H. Cho, J. H. Gong, M. K. Kang et al., “Astragalin inhibits airway eotaxin-1 induction and epithelial apoptosis through modulating oxidative stress-responsive MAPK signaling," *BMC Pulmonary Medicine*, vol. 14, no. 1, 2014.

[41] D. Qu, J. Han, H. Ren et al., “Cardioprotective effects of astragalin against myocardial ischemia/reperfusion injury in isolated rat heart," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 8194690, 11 pages, 2016.

[42] J. Han, D. Wang, B. Yu et al., “Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts," *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 134862, 11 pages, 2014.

[43] M. Zhou, L. Liu, W. Wang et al., “Role of licochalcone C in cardioprotection against ischemia/reperfusion injury of isolated rat heart via antioxidant, anti-inflammatory, and anti-apoptotic activities," *Life Sciences*, vol. 132, pp. 27–33, 2015.

[44] J. Qian, F. Jiang, B. Wang et al., “Ophiopogonin D prevents H2O2-induced injury in primary human umbilical vein endothelial cells," *Journal of Ethnopharmacology*, vol. 128, no. 2, pp. 438–445, 2010.

[45] M. Jiang, L. Kang, Y. Wang et al., “A metabonomic study of cardioprotection of ginsenosides, schizandrin, and ophiopogonin D against acute myocardial infarction in rats," *BMC Complementary and Alternative Medicine*, vol. 14, no. 1, p. 350, 2014.

[46] Q. Huang, B. Gao, L. Wang et al., “Ophiopogonin D: a new herbal agent against osteoporosis," *Bone*, vol. 74, pp. 18–28, 2015.

[47] W. You, T. Zhou, Z. Ma et al., “Ophiopogonin D maintains Ca2+ homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/EEIs and suppressing ER stress," *Acta Pharmacologica Sinica*, vol. 37, no. 3, pp. 368–381, 2016.

[48] X. Huang, Y. Wang, W. Yang, L. Yang, J. Wang, and Y. Gao, “Ophiopogonin D reduces myocardial ischemia-reperfusion injury via upregulating CYP2J3/EEIs in rats," *Cellular Physiology and Biochemistry*, vol. 49, no. 4, pp. 1646–1658, 2018.

[49] X. Y. Huang, Y. G. Wang, Z. Y. Zhang et al., “Ophiopogonin D and EETs ameliorate Ang II induced inflammatory responses via activating PPARα in HUVECs," *Biochemical and Biophysical Research Communications*, vol. 490, no. 2, pp. 123–133, 2017.

[50] J. Seubert, B. Yang, J. A. Bradbury et al., “Enhanced postchymic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway," *Circulation Research*, vol. 95, no. 5, pp. 506–514, 2004.
[51] T. Morimoto, Y. Sunagawa, T. Kawamura et al., “The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 868–878, 2008.
[52] S. Ahuja, S. Kohli, S. Krishnan, D. Dogra, D. Sharma, and V. Rani, “Curcumin: a potential therapeutic polyphenol, prevents noradrenaline-induced hyper trophy in rat cardiac myocytes,” The Journal of Pharmacy and Pharmacology, vol. 63, no. 12, pp. 1604–1612, 2011.
[53] S. Kumphune, S. Surinkaw, S. Chattipakorn, and N. Chattipakorn, “Inhibition of p38 MAPK activation protects cardiac mitochondria from ischemia/reperfusion injury,” Pharmacological Biology, vol. 53, no. 12, pp. 1831–1841, 2015.
[54] H. J. Liu, C. H. Wang, Z. Qiao, and Y. Xu, “Protective effect of curcumin against myocardial injury in ischemia reperfusion rats,” Pharmacological Biology, vol. 55, no. 1, pp. 1144–1148, 2017.
[55] O. S. Kim, E. J. Park, E. Joe, and I. Jou, “JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells,” Journal of Biological Chemistry, vol. 277, no. 43, pp. 40594–40601, 2002.
[56] S. O. Cho, J. W. Lim, and H. Kim, “Red ginseng extract inhibits the expression of MCP-1 and iNOS in Helicobacter pylori-infected gastric epithelial cells by suppressing the activation of NADPH oxidase and Jak2/Stat3,” Journal of Ethnopharmacology, vol. 150, no. 2, pp. 761–764, 2013.
[57] D. Guo, J. Li, Y. Wang, L. Lei, C. Yu, and N. Chen, “Cycloviroxobuxin D suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages in vitro by blocking JAK-STAT signaling pathway,” Acta Pharmacologica Sinica, vol. 35, no. 6, pp. 770–778, 2014.
[58] B. Chen, M. S. Longtine, and D. M. Nelson, “Punicalagin, a polyphenol in pomegranate juice, downregulates p53 and attenuates hypoxia-induced apoptosis in cultured human placental syncytiotrophoblasts,” American Journal of Physiology-Endocrinology and Metabolism, vol. 305, no. 10, pp. E1274–E1280, 2013.
[59] L. Yaidikar, B. Byna, and S. R. Thakur, “Neuroprotective effect of punicalagin against cerebral ischemia reperfusion-induced oxidative brain injury in rats,” Journal of Stroke and Cerebrovascular Diseases, vol. 23, no. 10, pp. 2869–2878, 2014.
[60] M. Ding, Y. Wang, D. Sun et al., “Punicalagin pretreatment attenuates myocardial ischemia-reperfusion injury via activation of AMPK,” The American Journal of Chinese Medicine, vol. 45, no. 01, pp. 53–66, 2017.
[61] K. Cao, J. Xu, W. Pu et al., “Punicalagin, an active component in pomegranate, ameliorates cardiac mitochondrial impairment in obese rats via AMPK activation,” Scientific Reports, vol. 5, no. 1, article 14014, 2015.
[62] R. Y. Lam, A. Y. H. Woo, P. S. Leung, and C. H. K. Cheng, “Antioxidant actions of phenolic compounds found in dietary plants on low-density lipoprotein and erythrocytes in vitro,” Journal of the American College of Nutrition, vol. 26, no. 3, pp. 233–242, 2007.
[63] P. Zhang, X. Liu, G. Huang, C. Bai, Z. Zhang, and H. Li, “Barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury via activation of AMPK,” Biochemical and Biophysical Research Communications, vol. 490, no. 4, pp. 1215–1220, 2017.
[64] X. Ren, X. Wang, M. Yuan et al., “Mechanisms and treatments of oxidative stress in atrial fibrillation,” Current Pharmaceutical Design, vol. 24, no. 26, pp. 3062–3071, 2018.
[65] D. K. Patel, K. Patel, and V. Tahiliani, “Barbaloin: a concise report of its pharmacological and analytical aspects,” Asian Pacific Journal of Tropical Biomedicine, vol. 2, no. 10, pp. 835–838, 2012.
[66] R. Wang and X. C. Tang, “Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease,” Neurosignals, vol. 14, no. 1-2, pp. 71–82, 2005.
[67] W. Yu, Q. Liu, and S. Zhu, “Carvacrol protects against acute myocardial infarction of rats via anti-oxidative and anti-apoptotic pathways,” Biological & Pharmaceutical Bulletin, vol. 36, no. 4, pp. 579–584, 2013.
[68] C. Meng, C. Liu, Y. Liu, and F. Wu, “Oxysporohidine attenuates the injury caused by acute myocardial infarction in rats through anti-oxidative, anti-inflammatory and anti-apoptotic pathways,” Molecular Medicine Reports, vol. 11, no. 1, pp. 527–532, 2015.
[69] D. N. Müller, E. M. A. Mervaala, R. Dechend et al., “Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy,” The American Journal of Pathology, vol. 157, no. 1, pp. 111–122, 2000.
[70] E. Speir, “Cytomegalovirus gene regulation by reactive oxygen species. Agents in atherosclerosis,” Annals of the New York Academy of Sciences, vol. 899, pp. 363–374, 2000.
[71] N. R. Wu, L. Chun, and B. G. Khas, “Euskeni folk medicinal plants and its comparison with Mongolian medicine,” Chinese Journal of Ethnomedicine and Ethnopharmacy, vol. 17, pp. 156–159, 2009.
[72] H. X. Kuang, G. S. Wu, H. Liu et al., “Isolation and identification of xanthones from Gentianella acuta,” Zhongguo Zhong Yao Za Zhi, vol. 41, no. 12, pp. 2280–2283, 2016.
[73] H. Marona, T. Librowski, M. Ceg, C. Erdogan, and N. O. Sahin, “Antiahrhythmic and anti hypertensive activity of some xanthisene derivatives,” Acta Poloniae Pharmaceutica, vol. 65, no. 3, pp. 383–390, 2008.
[74] G. Mahendran, M. Manoj, E. Muruges et al., “In vivo anti-diabetic, antioxidant and molecular docking studies of 1, 2, 8-trihydroxy-6-methoxy xanthone and 1, 2-dihydroxy-6-methoxyxanthone-8-O-β-d-xylpyranosyl isolated from Swertia corymbosa,” Phytomedicine, vol. 21, no. 11, pp. 1237–1248, 2014.
[75] C. Tantapakul, W. Maneerat, S. Srisupit et al., “New benzo-phenones and xanthones from Cratoxylum sumatranaum ssp. nerifolium and their antibacterial and antioxidant activities,” Journal of Agricultural and Food Chemistry, vol. 64, no. 46, pp. 8755–8762, 2016.
[76] M. Kavitha, J. Nataraj, M. M. Essa, M. A. Memon, and T. Manivasagam, “Huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease,” Cytomegalovirus gene regulation by reactive oxygen species. Agents in atherosclerosis,” Annals of the New York Academy of Sciences, vol. 899, pp. 363–374, 2000.
[77] X. Yang, N. Liu, X. Li et al., “The in vivo anti-diabetic, antioxidant and molecular docking studies of 1, 2, 8-trihydroxy-6-methoxy xanthone and 1, 2-dihydroxy-6-methoxyxanthone-8-O-β-d-xylpyranosyl isolated from Swertia corymbosa,” Phytomedicine, vol. 21, no. 11, pp. 1237–1248, 2014.
[78] S. Yang, G. Chou, and Q. Li, “Carvacrol protects against acute myocardial infarction in rats via activation of the Nrf2-ARE pathway,” Phytomedicine, vol. 47, pp. 12–22, 2018.
Oxidative Medicine and Cellular Longevity

[79] T. W. Kensler, N. Wakabayashi, and S. Biswal, “Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway,” Annual Review of Pharmacology and Toxicology, vol. 47, no. 1, pp. 89–116, 2007.

[80] Z. Q. Zhang, Z. H. Xing, T. Tang, W. P. Liu, and L. Yi, “Influence of baxoxin decoction on serum VEGF in patients with myocardial infarction after PTCA,” Journal of Beijing University of Traditional Chinese Medicine, vol. 29, no. 4, pp. 277–278, 2006.

[81] Y. Wang, W. Wang, W. Peng et al., “Cardioprotective roles of the Chinese medicinal formula Bao-Xin-Tang on acute myocardial infarction in rats,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 14, no. 2, pp. 65–74, 2017.

[82] Q. Shang, H. Wang, S. Li, and H. Xu, “The effect of sodium Tanshinone II A sulfate and simvastatin on elevated serum levels of inflammatory markers in patients with coronary heart disease: a study protocol for a randomized controlled trial,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 756519, 8 pages, 2013.

[83] P. V. Kiruthiga, R. B. Shafreen, S. K. Pandian, S. Arun, S. Govindu, and K. P. Devi, “Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress,” Chemosphere, vol. 68, no. 8, pp. 1511–1518, 2007.

[84] M. Xie, “Sheng-Mai-San and Dan-Shen-Yin treat coronary heart disease 60 cases,” Chinese Medicine Modern Distance Education of China, vol. 6, no. 11, p. 1357, 2008.

[85] R. S. Liu, “Jia-Wei-Dan-Shen-Yin treat coronary heart disease 68 cases,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 8, no. 5, p. 604, 2010.

[86] K.-P. Yan, Y. Guo, Z. Xing et al., “Dan-Shen-Yin protects the heart against inflammation and oxidative stress induced by acute ischemic myocardial injury in rats,” Experimental and Therapeutic Medicine, vol. 3, no. 2, pp. 314–318, 2012.

[87] P. Krishnamurthy, E. Lambers, S. Verma et al., “Myocardial knockdown of miRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice,” The FASEB Journal, vol. 24, no. 7, pp. 2484–2494, 2010.

[88] X. Li, X. Yang, Y. Li et al., “Mitochondria and the pathophysiological mechanism of atrial fibrillation,” Current Pharmaceutical Design, vol. 24, no. 26, pp. 3055–3061, 2018.

[89] M. Yuan, N. Liu, X. Wang et al., “The mechanism of exosomes function in neurological diseases: a progressive review,” Current Pharmaceutical Design, vol. 24, no. 24, pp. 2855–2861, 2018.

[90] L. A. Zhen, Z. X. Ying, D. Tao, W. H. Qing, G. J. Yan, and W. Liang, “Therapeutic effect of Danhong injection combined with Dunye Guanxinning tablet on acute myocardial infarction and its effect on platelet activation biomarkers,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 25, no. 6, pp. 615–617, 2016.

[91] Q. G. Zhang, S. R. Wang, X. M. Chen, H. N. Guo, S. Ling, and J. W. Xu, “Dunye Guanxinning improves acute myocardial ischemia-reperfusion injury by inhibiting neutrophil infiltration and caspase-1 activity,” Mediators of Inflammation, vol. 2018, Article ID 4608017, 13 pages, 2018.

[92] M. Qi, M. Y. Tang, H. Q. Zhou, and Y. Zhou, “Clinical observation of sofren injection in the treatment of angina pectoris,” China Modern Doctor, vol. 54, no. 21, pp. 139–144, 2016.

[93] S. Zhang, L. Zhang, H. Zhang et al., “Hongjingtian injection attenuates myocardial oxidative damage via promoting autophagy and inhibiting apoptosis,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 6965739, 11 pages, 2017.

[94] T. Wu, H. Zhou, Z. Jin et al., “Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylcysteine linkage to cellular proteins,” European Journal of Pharmacology, vol. 613, no. 1–3, pp. 93–99, 2009.

[95] K. Shi, X. Wang, J. Zhu, G. Cao, K. Zhang, and Z. Su, “Salidroside protects retinal endothelial cells against hydrogen peroxide-induced injury via modulating oxidative status and apoptosis,” Bioscience, Biotechnology, and Biochemistry, vol. 79, no. 9, pp. 1406–1413, 2015.

[96] Y. Wang and D. L. Cai, “Clinical observation on the treatment of unstable angina pectoris with Guanxintai pills,” Heilongjiang Medicine and Pharmacy, vol. 34, no. 3, p. 104, 2011.

[97] Y. Z. Zhang, “Observation of curative effect of Guanxintai pills on angina pectoris,” Clinical Rational Drug Use, vol. 5, no. 2C, pp. 74–75, 2012.

[98] X. P. Bai, “Clinical observation on the treatment of unstable angina pectoris with Guanxintai,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 20, no. 22, pp. 2763–2766, 2011.

[99] L. Q. Song, X. D. Zhang, L. P. Zhao, M. L. Zhang, X. H. Han, and D. Sun, “Observation of curative effect of Guanxintai on angina pectoris,” Practical Journal of Cardiac Cerebral Pneumonial and Vascular Disease, vol. 20, no. 3, p. 464, 2012.

[100] Y. H. Qi, M. L. Zhang, and L. Yin, “The 34 cases of the patients with ventricular premature beats treated with Guanxintai and amiodarone hydrochloride tablets,” Guide of China Medicine, vol. 10, no. 10, pp. 301–302, 2012.

[101] C. Y. Sun and R. Y. Wang, “Clinical efficacy of Guanxintai pills combined with Western medicine on the treatment of angina pectoris combined with hyperlipidemia,” China Medical Engineering, vol. 19, no. 2, pp. 49–51, 2011.

[102] J. Yang, W. Sun, J. Sun et al., “Guanxintai exerts protective effects on ischemic cardiomyocytes by mitigating oxidative stress,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 4534387, 10 pages, 2017.

[103] F. Y. Guan, H. Li, X. Y. Yu, and S. J. Yang, “Effects of astragalus injection on myocardial cell damages due to oxidative stress,” Chinese Journal of Rehabilitation Theory and Practice, vol. 16, no. 9, pp. 830–832, 2010.

[104] D. F. Zhang, M. W. Wang, L. S. Wang et al., “Effect of salvianolate on oxidative stress and brain natriuretic peptide in acute myocardial infarction,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 6, no. 11, pp. 1304–1306, 2008.

[105] X. Y. Yang, N. Zhao, Y. Y. Liu et al., “Inhibition of NADPH oxidase mediates protective effect of cardiotoxic pills against rat heart ischemia/reperfusion injury,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 728020, 15 pages, 2013.

[106] N. Zhao, Y. Y. Liu, F. Wang et al., “Cardiotoxic pills, a compound Chinese medicine, protects ischemia-reperfusion-induced microcirculatory disturbance and myocardial damage in rats,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 4, pp. H1166–H1176, 2010.
Oxidative Medicine and Cellular Longevity

[107] H. Y. Son, H. S. Han, H. W. Jung, and Y.-K. Park, "Panax notoginseng attenuates the infarct volume in rat ischemic brain and the inflammatory response of microglia," Journal of Pharmacological Sciences, vol. 109, no. 3, pp. 368–379, 2009.

[108] J. H. Hu, S. J. Chen, and X. L. Hua, "Clinical research of Shexianshengma oral liquid in the treatment of sick sinus syndrome and sinus bradycardia," Chinese Traditional Patent Medicines, vol. 34, no. 1, pp. 7–9, 2012.

[109] P. Li and L. Zeng, "Clinical observation of Shexianshengma oral liquid in the treatment of bradycardia," Chinese Journal of Integrative Medicine on Cardio, vol. 9, no. 9, pp. 1121-1122, 2011.

[110] Y. Zhao, X. Zhang, J. Luan et al., "Shenxian-Shengma oral liquid reduces myocardial oxidative stress and protects myocardium from ischemia-reperfusion injury," Cellular Physiology and Biochemistry, vol. 48, no. 6, pp. 2503–2516, 2018.

[111] Z. Y. Liu, J. Huang, N. N. Liu et al., "Molecular mechanisms of increased heart rate in Shexianshengma-treated bradycardia rabbits," Chinese Medical Journal, vol. 130, no. 2, pp. 179–186, 2017.

[112] C. Hong, Y. Wang, J. Lou, Q. Liu, H. Qu, and Y. Cheng, "Analysis of myocardial proteomic alteration after QishenYiqi formula treatment in acute infarcted rat hearts," Zhongguo Zhong Yao Za Zhi, vol. 34, no. 8, pp. 1018–1021, 2009.

[113] G. H. Dai, B. L. Zhang, and Z. X. Guo, "Application of central randomized system in project of clinical trial for secondary prevention of myocardial infarction by Qishen Yiqi drop pill," Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 27, no. 7, pp. 653–656, 2007.

[114] C. Li, Y. Wang, Q. Qiu et al., "QishenYiqi protects against pressure overload-induced ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-kB signaling pathway," PLoS One, vol. 9, no. 8, article e104255, 2014.

[115] Y. Wang, C. Li, Y. Ouyang et al., "Cardioprotective effects of QishenYiqi mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin-converting enzyme 2," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 978127, 9 pages, 2012.

[116] L. Zhang, Y. Liu, X. T. Lu et al., "Traditional Chinese medicine Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy," American Journal of Physiology-Heart and Circulatory Physiology, vol. 297, no. 6, pp. H2004–H2014, 2009.

[117] B. Wang, Q. Yang, W. B. Bai et al., "Tongxinluo protects against pressure overload–induced heart failure in mice involving VEGF/Akt/eNOS pathway activation," PLoS One, vol. 9, no. 6, article e98047, 2014.

[118] W. W. Bai, Y. F. Xing, B. Wang et al., "Tongxinluo improves cardiac function and ameliorates ventricular remodeling in mice model of myocardial infarction through enhancing angiogenesis," Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 813247, 9 pages, 2013.

[119] G. S. Cao, H. L. Chen, Y. Y. Zhang et al., "YiQiFuMai powder injection ameliorates the oxygen-glucose deprivation-induced brain microvascular endothelial barrier dysfunction associated with the NF-kB and ROCK1/MLC signaling pathways," Journal of Ethnopharmacology, vol. 183, pp. 18–28, 2016.

[120] Y. Q. Wang, C. H. Liu, J. Q. Zhang, D. N. Zhu, and B. Y. Yu, "Protective effects and active ingredients of Yi-Qi-Fu-Mai sterile powder against myocardial oxidative damage in mice," Journal of Pharmacological Sciences, vol. 122, no. 1, pp. 17–27, 2013.

[121] L. Z. Pang, A. C. Ju, X. J. Zheng et al., "YiQiFuMai powder injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway," Journal of Ethnopharmacology, vol. 202, pp. 67–77, 2017.

[122] L. Xing, M. Jiang, L. Dong et al., "Cardioprotective effects of the YiQiFuMai injection and isolated compounds on attenuating chronic heart failure via NF-kB inactivation and cytokine suppression," Journal of Ethnopharmacology, vol. 148, no. 1, pp. 239–245, 2013.

[123] E. P. Daskalopoulos, C. Dufeyes, L. Bertrand, C. Beauloye, and S. Hormann, "AMPK in cardiac fibrosis and repair: actions beyond metabolic regulation," Journal of Molecular and Cellular Cardiology, vol. 91, pp. 188–200, 2016.

[124] Y.-Q. Feng, A.-C. Ju, C.-H. Liu, T. Wang, B.-Y. Yu, and J. Qi, "Protective effect of the extract of Yi-Qi-Fu-Mai preparation on hypoxia-induced heart injury in mice," Chinese Journal of Natural Medicines, vol. 14, no. 6, pp. 401–406, 2016.

[125] F. Li, X. Zheng, X. Fan et al., "YiQiFuMai powder injection attenuates ischemia/reperfusion-induced myocardial apoptosis through AMPK activation," Rejuvenation Research, vol. 19, no. 6, pp. 495–508, 2016.

[126] National Pharmacopoeia Committee, Pharmacopoeia of the People’s Republic of China, China Medical Science and Technology Press, Bejing, China, 2015.

[127] X. Cai, J. du, L. Li et al., "Clinical metabolomics analysis of therapeutic mechanism of Tongmai Yangxin pill on stable angina," Journal of Chromatography B, vol. 1100-1101, pp. 106–112, 2018.

[128] S. Tao, X. Y. Liang, Y. Wang, and Y. Wang, "Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill," Zhejiang Da Xue Xue Bao Yi Xue Ban, vol. 44, no. 2, pp. 145–153, 2015.

[129] Y. Wang, L. Zhang, Y. Xiao, L. Zhang, and Y. Xing, "Effect of Tongmai Yangxin pills on inflammatory factors and oxidative stress of cardiomyocyte injury induced by hypoxia," Journal of Traditional Chinese Medicine, vol. 52, no. 4, pp. 326–328, 2011.

[130] K. Kumari and K. T. Augusti, "Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats," Journal of Ethnopharmacology, vol. 109, no. 3, pp. 367–371, 2007.

[131] L. S. Son, J. H. Kim, H. Y. Sohn, K. H. Son, J.-S. Kim, and C.-S. Kwon, "Antioxidative and hypolipidemic effects of Dioscorea spp., a high-cholesterol fed rats," Bioscience, Biotechnology, and Biochemistry, vol. 71, no. 12, pp. 3063–3071, 2007.

[132] W. Xia, C. Sun, Y. Zhao, and L. Wu, "Hypolipidemic and antioxidant activities of Sanchi (Radix Notoginseng) in rats fed with a high fat diet," Phytomedicine, vol. 18, no. 6, pp. 516–520, 2011.

[133] Q. Li, Y. H. Ye, and Q. Y. Xing, "Progress on the water-soluble constituents and its pharmacology of Panax notoginseng," Chemical Research in Chinese Universities, vol. 17, no. 12, pp. 1886–1892, 1996.

[134] X. J. Wang and P. Feng, "Antioxidant activity of qizhu tang," Acta Pharmacologica Sinica, vol. 21, no. 12, pp. 1141-1144, 2000.

[135] A. Basu and K. Penugonda, "Pomegranate juice: a heart-healthy fruit juice," Nutrition Reviews, vol. 67, no. 1, pp. 49–56, 2009.
[136] M. Hassanpour Fard, A. E. Ghule, S. L. Bodhankar, and M. Dikshit, “Cardioprotective effect of whole fruit extract of pomegranate on doxorubicin-induced toxicity in rat,” *Pharmaceutical Biology*, vol. 49, no. 4, pp. 377–382, 2011.

[137] M. Aviram, M. Rosenblat, D. Gaitini et al., “Pomegranate juice consumption for 3 years with patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation,” *Clinical Nutrition*, vol. 23, no. 3, pp. 423–433, 2004.

[138] A. Al-Jarallah, F. Igdoura, Y. Zhang et al., “The effect of pomegranate extract on coronary artery atherosclerosis in SR-BI/APOE double knockout mice,” *Atherosclerosis*, vol. 228, no. 1, pp. 80–89, 2013.

[139] L. Wang, H. Nishida, Y. Ogawa, and T. Konishi, “Prevention of oxidative injury in PC12 cells by a traditional Chinese medicine, Shengmai San, as a model of an antioxidant-based composite formula,” *Biological & Pharmaceutical Bulletin*, vol. 26, no. 7, pp. 1000–1004, 2003.

[140] H. T. Yao, Y. W. Chang, C. T. Chen, M. T. Chiang, L. Chang, and T. K. Yeh, “Shengmai San reduces hepatic lipids and lipid peroxidation in rats fed on a high-cholesterol diet,” *Journal of Ethnopharmacology*, vol. 116, no. 1, pp. 49–57, 2008.

[141] J. S. You, H. F. Huang, Y. L. Chang, and Y. S. Lee, “Sheng-Mai San reduces adriamycin-induced cardiomyopathy in rats,” *The American Journal of Chinese Medicine*, vol. 34, no. 02, pp. 295–305, 2006.

[142] U. Forstermann, “Oxidative stress in vascular disease: causes, defense mechanisms, and potential therapies,” *Nature Clinical Practice. Cardiovascular Medicine*, vol. 5, no. 6, pp. 338–349, 2008.

[143] M. F. El-Refaei, S. H. Abduljawad, and A. H. Alghamdi, “Alternative medicine in diabetes - role of angiogenesis, oxidative stress, and chronic inflammation,” *The Review of Diabetic Studies*, vol. 11, no. 3-4, pp. 231–244, 2014.

[144] C. Lopez-Alarcon and A. Denicola, “Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays,” *Analytica Chimica Acta*, vol. 763, pp. 1–10, 2013.

[145] Y.-M. Lee, P.-Y. Cheng, S.-Y. Chen, M.-T. Chung, and J.-R. Sheu, “Wogonin suppresses arrhythmias, inflammatory responses, and apoptosis induced by myocardial ischemia/reperfusion in rats,” *Journal of Cardiovascular Pharmacology*, vol. 58, no. 2, pp. 133–142, 2011.

[146] S. Sanada, I. Komuro, and M. Kitakaze, “Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 301, no. 5, pp. H1723–H1741, 2011.

[147] L. Timmers, G. Pasterkamp, V. C. de Hoog, F. Arslan, Y. Appelman, and D. P. V. de Kleijn, “The innate immune response in reperfused myocardium,” *Cardiovascular Research*, vol. 94, no. 2, pp. 276–283, 2012.

[148] L.-N. Yu, J. Yu, F.-J. Zhang et al., “Sevoflurane postconditioning reduces myocardial reperfusion injury in rat isolated hearts via activation of PI3K/Akt signaling and modulation of Bcl-2 family proteins,” *Journal of Zhejiang University Science B*, vol. 11, no. 9, pp. 661–672, 2010.

[149] H.-F. Luan, Z.-B. Zhao, Q.-H. Zhao, P. Zhu, M.-Y. Xiu, and Y. Ji, “Hydrogen sulfide postconditioning protects isolated rat hearts against ischemia and reperfusion injury mediated by the JAK2/STAT3 survival pathway,” *Brazilian Journal of Medical and Biological Research*, vol. 45, no. 10, pp. 988–905, 2012.

[150] A. Dhanasekaran, S. K. Gruenloh, J. N. Buonacorsi et al., “Multiple anti-apoptotic targets of the PI3K/Akt survival pathway are activated by epoxycosatetraenonic acids to protect cardiomyocytes from hypoxia/anoxia,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 294, no. 2, pp. H724–H735, 2008.

[151] H. Zhu, Z. Jia, B. R. Misra et al., “Nuclear factor E2-related factor 2-dependent myocardial cytoprotection against oxidative and electrophilic stress,” *Cardiovascular Toxicology*, vol. 8, no. 2, pp. 71–85, 2008.

[152] V. G. Zaha, D. Qi, K. N. Su et al., “AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia,” *Journal of Molecular and Cellular Cardiology*, vol. 91, pp. 104–113, 2016.

[153] A. S. Kim, E. J. Miller, T. M. Wright et al., “A small molecule AMPK activator protects the heart against ischemia–reperfusion injury,” *Journal of Molecular and Cellular Cardiology*, vol. 51, no. 1, pp. 24–32, 2011.

[154] R. Khatib, P. Joseph, M. Briel, S. Yusuf, and J. Healey, “Blockade of the renin–angiotensin–aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials,” *International Journal of Cardiology*, vol. 165, no. 1, pp. 17–24, 2013.

[155] M. Zhang, A. Perino, A. Ghigo, E. Hirsch, and A. M. Shah, “NADPH oxidadses in heart failure: poachers or gamekeepers?,” *Antioxidants & Redox Signaling*, vol. 18, no. 9, pp. 1024–1041, 2013.

[156] K. Schröder, M. Zhang, S. Benkhoff et al., “Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase,” *Circulation Research*, vol. 110, no. 9, pp. 1217–1225, 2012.

[157] L. Gullesstad, T. Ueland, L. E. Vinge, A. Finsen, A. Yndestad, and P. Aukrust, “Inflammatory cytokines in heart failure: mediators and markers,” *Cardiology*, vol. 122, no. 1, pp. 23–35, 2012.

[158] X. Yang, Y. Li, Y. Li et al., “Oxidative stress-mediated atherosclerosis: mechanisms and therapies,” *Frontiers in Physiology*, vol. 8, p. 600, 2017.

[159] V. Malikka, B. Goswami, and M. Rajappa, “Atherosclerosis pathophysiology and the role of novel risk factors: a clinico-biochemical perspective,” *Angiology*, vol. 58, no. 5, pp. 513–522, 2007.

[160] W. Y. W. Lee, L. C. M. Chiu, and J. H. K. Yeung, “Cytotoxicity of major Tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation,” *Food and Chemical Toxicology*, vol. 46, no. 1, pp. 328–338, 2008.